FDA approves Janssen’s plaque psoriasis drug Tremfya
SILVER SPRING, Md. — The Food and Drug Adminisration has approved Janssen Biotech’s new treatment for plaque psoriasis, the company announced Thursday. Tremfya (guselkumab) is the first drug to be approved that selectively blocks a key plaque psoriasis cytokine, the company said.
“Addressing the need for additional safe and effective plaque psoriasis therapies has been a critical area of focus at Janssen for more than 15 years,” Janseen VP medical affairs Dr. Andrew Greenspan said. “Considering this, we applied a priority review voucher to the application for Tremfya to bring this novel treatment to patients sooner.”
The drug is indicated for moderate to severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy.
"Living with plaque psoriasis is challenging, especially the constant pain, itching and burning," said Patti Janick, a guselkumab clinical trial participant. "I am encouraged by the results I've experienced with TREMFYA™ and the possibility it offers others living with plaque psoriasis to find similar relief and clearer skin."
Janssen said it would work with payers, providers and pharmacy benefits managers to ensure broad accessibility and affordability for patients, and that the cost for payers is competitive with currently available psoriasis biologic treatments.
PhRMA adds 2 VPs
PrescribeWellness adds Central Sync to its StarWellness platform
IRVINE, Calif. — Cloud-based pharmacy services company PrescribeWellness is adding to its suite of medication synchronization solutions, StarWellness. The company is introducing Central Sync, which allows PrescribeWellness to reach out to both pharmacies and patients to identify, recruit and enroll patients with the most impact on a pharmacy’s adherence measures. It also has added an online training course.
“By participating in Central Sync, PrescribeWellness is primed to support pharmacies by increasing time for clinical interventions, as well as mitigating DIR fees,” PrescribeWellness associate director of pharmacy operations Poonam Gandhi said. “What’s more, Central Sync has been shown to increase medication adherence, improve Star Ratings and optimize the pharmacy refill workflow, improving business operations for pharmacies while enhancing patient care — providing a win-win.”
StarWellness is the official medication synchronization technology of the National Community Pharmacists Association’s Simplify My Meds program for community pharmacies. The platform’s new Med Sync Certification is an online training course designed to help a pharmacy and its staff implement a med sync program. Once the training is complete, the service uses PrescribeWellness pharmacists and technicians to identify a pharmacy’s top 25 patient candidates who would benefit most from med sync and calls to enroll them on behalf of the pharmacy.